Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Segmental Vapor Ablation Treatment of Emphysema With Upper Lobe Predominance: A Randomized Controlled Trial of InterVapor® in France - The TARGET Trial

NCT05118269 is registered in ClinicalTrials.gov with Uptake Medical Technology, Inc. as lead sponsor.

NCT NCT05118269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05118269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Segmental Vapor Ablation Treatment of Emphysema With Upper Lobe Predominance: A Randomized Controlled Trial of InterVapor® in France - The TARGET Trial
Lead sponsor
Uptake Medical Technology, Inc.
Phase
Not applicable
Overall status
Terminated
Start date
July 21, 2023
Completion date
June 4, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

emphysema